Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Q4-FY26"

48 News Found

Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion
Hospitals | May 18, 2026

Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion

Medanta expanded its bed capacity by 20% during the year


Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore
News | May 15, 2026

Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore

The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives


Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26
News | May 15, 2026

Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26

The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market


Senores Pharma doubles profit as sales surge 62%
News | May 15, 2026

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth


Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million
News | May 11, 2026

Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million

Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint


Thyrocare Q4 PAT surges 128% to Rs. 48.7 crore
Healthcare | May 08, 2026

Thyrocare Q4 PAT surges 128% to Rs. 48.7 crore

Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands


Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%
News | May 06, 2026

Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%

The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms


Wockhardt reports FY26 net profit of Rs 317 crore, Board approves fundraising plan
Biopharma | May 04, 2026

Wockhardt reports FY26 net profit of Rs 317 crore, Board approves fundraising plan

Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance